P.A. Konstantinopoulos

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.

R. T. Penson, Charles J. Whalen, Brian Lasonde et al. · Journal of Clinical Oncology · 2011 · 33 citations

A phase II trial of combination nivolumab and bevacizumab in recurrent ovarian cancer

J.F. Liu, Christina I. Herold, Wenjie Luo et al. · Annals of Oncology · 2018 · 22 citations · Full text

NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss

Filip Jankú, Opeyemi A. Jegede, Shannon L. Puhalla et al. · Annals of Oncology · 2018 · 11 citations · Full text

LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

P.A. Konstantinopoulos, A.A. Gockley, Niya Xiong et al. · Annals of Oncology · 2020 · 11 citations · Full text

Medicine, Gynecology, Pd-l1 Inhibitor Avelumab +6

Phase II study of pembrolizumab (pembro) combined with pegylated liposomal doxorubicin (PLD) for recurrent platinum-resistant ovarian, fallopian tube or peritoneal cancer

U.A. Matulonis, W Barry, R. T. Penson et al. · Gynecologic Oncology · 2018 · 10 citations

Pegylated Liposomal Doxorubicin, Medicine, Gynecology +9